

EFGCP ANNUAL

PAEDIATRIC CONFERENCE



VIRTUAL EVENT

BETTER MEDICINES FOR CHILDREN

Global Paediatric Drug Development
Progress made & always remaining challenges

18&19
October
2022



AGENDA AT A GLANCE

TUESDAY 18 OCTOBER 2022

11:45 Opening of Conference

12:00 Welcome and Introduction to the Conference

12:10 PDCO Vision

12:40 Implementation of the CT Regulation 536/2014 – Impact on Paediatric trials

13:30 Panel discussion: Global / transatlantic alignment for the development of paediatric products – what can be learnt from paediatric oncology drug development?

14:30 Coffee break

14:45 Panel session: Rare diseases – what is happening and can be expected?
EU Commission/EU joint program on rare diseases

15:45 Breakout sessions:

- How to improve Patient & Parents involvement in Paediatric Research?
- Paediatric Lay Summaries
- Is it time to prioritise?

17:15 Fireside Chat

18:15 End of Day 1

WEDNESDAY 19 OCTOBER 2022

11:45 Opening of Conference

12:00 Welcome and Debrief from Day 1

12:10 Panel Session: Optimising Paediatric Drug Development – what progress has been made since the 2021 Paediatric Conference?

13:30 Panel Session: Neonatal Research – where are we and what could be next steps?

14:30 Panel Session: What's new at ICH for paediatric drug development?

15:30 Coffee break

15:50 Panel Session: Can drug repurposing benefit drug development in Children & in Paediatric Rare Diseases?

16:50 Feedback from the Breakout Sessions

17:50 End of Day 2 – Conclusion & Farewell

The EFGCP “Better Medicines for Children” Conference is an annual flagship event providing a unique opportunity to share best practice, reflect on what has happened since we last met in October 2021, and discuss paediatric updates with a truly global outreach. Despite an ever changing and challenging environment, and the need to meet virtually again, we believe we have been able to organise a dynamic, innovative, and highly engaging conference to inform our delegates of the latest scientific and regulatory developments.

The conference will focus on **Global Paediatric Development**, its challenges and solutions, and in particular on what has been achieved during the pandemic, and the remaining opportunities and challenges. To this effect, the conference brings together not only distinguished speakers from all around the world but also all the stakeholders involved in paediatric drug development.

Day One will bring regulators and patient representatives to discuss the potential impact on R&D of the **revision of paediatric regulation** and of the **implementation of the Clinical Trial Regulation**. Stakeholders from around the world while focusing on **global alignment** will share their view on what can be learnt from paediatric oncology drug development. A panel committed to finding solutions for **rare diseases**, which present a unique public health challenge, will discuss the latest information on rare diseases.

Active engagement of conference delegates will be then welcomed in **Breakout Sessions** to discuss challenges and identify solutions on what could be done to optimise children’s access to new medicines, with a focus on important topics:

1. How to improve Patient and parents’ involvement in Paediatric research?
2. Paediatric Lay Summaries
3. Is it time to prioritise?

At the end of Day 1, a **fireside chat** will be the opportunity to hear from Dr Koen Norga (previous PDCO chair), and Dr Angeliki Siapkara (MHRA and former UK representative on PDCO) about their respective activities and priorities; and also to hear their view and answers to questions raised ahead of the conference.

Day two will be the opportunity to keep the momentum with experts who joined the 2021 conference. Hot paediatric topics for which multi-stakeholders’ collaboration is more than ever valued to address gaps in scientific knowledge, will explore innovative development avenues that could foster paediatric drug development.

The programme committee looks forward to welcoming you all to the conference for a global educational and networking event that is a unique opportunity to learn from one another, to meet and interact with colleagues from all parts of the world.

We do hope that the 2022 conference will be the last one organised remotely, and 2023 will give us to go back to face-to-face meetings.

NEWS! For those interested in paediatric drug development, a pre-conference Workshop on **the "Fundamentals of Paediatric Extrapolation"** has been set up on October 17. This will be the opportunity to learn from the experts the value of paediatric extrapolation, a topic detailed in the ICH E11 guideline recently released for public consultation. For further details on this pre-conference Workshop, please visit the webpage.

Thank you for joining us!

◆ ACKNOWLEDGEMENT ◆

EFGCP Thanks its Partners & Members for their continued support

In partnership with



With the support of



EFGCP Corporate Members



EFGCP Institutional Members



Avicenna Alliance
Association for Predictive Medicine



UNIVERSIDAD RAMON LLULL



Clinical Research Network



swissethics



Vienna Vaccine Safety Initiative

Medical Ethical Review Board



UiO : University of Oslo



Alexandru Costescu
Angelika Joos
Angeliki Siapkara
Begonya Nafria Escalera
Gilles Vassal
Helen Shaw
Koenraad Norga
Martine Dehlinger-Kremer
Rhian Thomas-Turner
Sabine Fuerst-Recktenwald
Solange Corriol-Rohou
Thomas Severin

European Commission, Belgium
MSD, Belgium
MHRA, United Kingdom
Sjd Children's Hospital Barcelona, Spain
Gustave Roussy Institute, France
Proveca, United Kingdom
Antwerp University Hospital, Belgium & previous Chair of EMA PDCO, NL
EFGCP, EUCROF & ICON Plc., Germany
NHS, United Kingdom
Roche, Switzerland
AstraZeneca, France
Novartis, Switzerland

Faculty

Alexandru Costescu
Ann Marie Janson Lang
Angeliki Siapkara
Begonya Nafria Escalera
Billy Amzal
Brian Aylward
Christina Bucci-Rechtweg
Christina Kyriakopoulou
Claudio Fracasso
Corinne de Vries
David Hayes
Dimitrios Athanasiou
Dominik Karres
François Houyez
Gilles Vassal
Gunter Egger
Helen Mao
Hannah Batchelor
Isaac Rodriguez-Chavez
Jeffrey Barrett
John van den Anker
Kaye Robertson
Koenraad Norga
Kristin Karlsson
Kristina An Hack
Lynne Yao
Marie-Yvonne Douste-Blazy
Mark Turner
Martha Donoghue
Martine Dehlinger-Kremer
Nicola Ruperto
Nicolas Frey
Pamela Dicks
Ralph Bax
Rhian Thomas-Turner
Sabine Fuerst-Recktenwald
Sam Blackman
Solange Corriol-Rohou
Susan McCune

European Commission, Belgium
Swedish MPA, Sweden
MHRA, United Kingdom
Sjd Children's Hospital Barcelona, Spain
Quinten Health, France
Chair PDCO, EMA
Novartis, USA
European Commission, Belgium
Pfizer, Italy
EMA, The Netherlands
AstraZeneca, USA
EURORDIS, Greece
EMA, The Netherlands
EURORDIS, France
Gustave Roussy Institute, France
Enpr-EMA, EMA, the Netherlands
Health Canada, Canada
Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Scotland
ICON, USA
Critical-Path Initiative, USA
Children's National Medical Center Washington, DC, USA
TGA, Australia
Antwerp University Hospital, Belgium & previous Chair of EMA PDCO, NL
Swedish MPA, Sweden
Sanofi, France
FDA, USA
MYDB Paediatric Clinical Insights, France
Liverpool University, United Kingdom
FDA, USA
EFGCP, EUCROF & ICON Plc., Germany
PRINTO, Italy
Roche, Switzerland
NHS, United Kingdom
EMA, the Netherlands
NHS, United Kingdom
Roche, Switzerland
DayOne, USA
AstraZeneca, France
PPD, USA



EFGCP
ANNUAL PAEDIATRIC CONFERENCE

BETTER MEDICINES FOR CHILDREN
Global Paediatric Drug Development
Progress made & always remaining challenges

Conference Language: English

Information & Registrations

- [Click Here](#) -

events@efgcp.eu



◇ VIRTUAL EVENT